Want to see SE:BIOSGN full AI Analyst Report?
Top Page
Biosergen AB
(BIOSGN)
Select Model
Select Model
Rating:41Neutral
Price Target:
kr0.52
▼(-98.78% Downside)
Action:Reiterated
Date:09/16/26
The score is primarily held down by weak financial performance—near-zero revenue, sizable ongoing losses, heavy negative free cash flow, and sharply reduced equity that increases reliance on external funding. Technicals also remain bearish with the price far below major moving averages and a negative MACD, only modestly offset by oversold signals. Valuation offers limited support due to a negative P/E and no dividend yield data.
Positive Factors
Focused antifungal pipeline
The company has a clearly defined therapeutic focus and a lead asset addressing invasive fungal infections. Concentrating resources on BSG005 may help align research priorities, clinical development, and potential partnering efforts around one identifiable platform opportunity.
Negative Factors
No visible revenue base
The absence of a visible revenue base means the company has not yet demonstrated commercial monetization in its reported financials. This leaves future operating economics dependent on successful development, regulatory progress, and eventual product or partnership income.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused antifungal pipeline
The company has a clearly defined therapeutic focus and a lead asset addressing invasive fungal infections. Concentrating resources on BSG005 may help align research priorities, clinical development, and potential partnering efforts around one identifiable platform opportunity.
Read all positive factors
Biosergen AB (BIOSGN) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr43.82M
Dividend YieldN/A
Average Volume (3M)694.28K
Price to Earnings (P/E)―
Beta (1Y)0.47
Revenue GrowthN/A
EPS Growth24.27%
CountrySE
Employees1
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.61
Shares Outstanding82,684,270
10 Day Avg. Volume1,371,306
30 Day Avg. Volume694,277
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)72.03
Price to Sales (P/S)0.00
P/FCF Ratio-23.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.1
Revenue Forecast (FY)kr1.40M
Biosergen AB Business Overview & Revenue Model
Company Description
Biosergen AB is a biopharmaceutical company specializing in the creation of antifungal medications. Its key development initiative is BSG005, an experimental antifungal drug candidate engineered to treat critical invasive fungal infections. The fi...
How the Company Makes Money
Biosergen AB is an R&D-stage biotechnology company; specific, recurring commercial revenue streams from marketed products are not publicly available in the provided context. As a result, a definitive breakdown of how the company currently makes mo...
Biosergen AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
34
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.57M |
| Gross Profit | 0.00 | 0.00 | 0.00 | -456.00K | -280.00K | -213.60K |
| EBITDA | -24.66M | -40.84M | -19.20M | 228.00K | -34.05M | -34.32M |
| Net Income | -35.12M | -40.82M | -19.20M | -27.04M | -34.05M | -34.32M |
Balance Sheet | ||||||
| Total Assets | 10.24M | 19.83M | 52.85M | 7.20M | 33.79M | 29.49M |
| Cash, Cash Equivalents and Short-Term Investments | 3.23M | 15.37M | 50.61M | 1.88M | 29.34M | 21.66M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 9.53M | 8.06M | 3.71M | 5.08M | 11.00M | 9.25M |
| Stockholders Equity | 704.00K | 11.76M | 48.21M | 2.12M | 22.79M | 20.23M |
Cash Flow | ||||||
| Free Cash Flow | -31.46M | -36.81M | -16.63M | -32.60M | -29.44M | -37.75M |
| Operating Cash Flow | -31.46M | -36.81M | -16.63M | -32.60M | -29.44M | -37.75M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | -38.00K | -38.00K | 65.36M | 5.14M | 37.12M | 58.83M |
Biosergen AB Technical Analysis
Negative
42.60
Price Trends
1.46
Negative
1.16
Negative
2.47
Negative
Market Momentum
-0.36
Positive
38.70
Neutral
0.69
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOSGN, the sentiment is Negative. The current price of 42.6 is above the 20-day moving average (MA) of 1.12, above the 50-day MA of 1.46, and above the 200-day MA of 2.47, indicating a bearish trend. The MACD of -0.36 indicates Positive momentum. The RSI at 38.70 is Neutral, neither overbought nor oversold. The STOCH value of 0.69 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BIOSGN.
Biosergen AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | kr423.20M | 2.15 | 63.09% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr214.30M | -4.42 | -13.41% | ― | -68.66% | -137.27% | |
48 Neutral | kr182.52M | -7.68 | -56.09% | ― | ― | 14.10% | |
48 Neutral | kr429.45M | -3.64 | -18.05% | ― | ― | 15.97% | |
43 Neutral | kr1.37B | -2.95 | -99.58% | ― | -87.22% | -70.29% | |
41 Neutral | kr43.82M | -0.09 | -420.21% | ― | ― | 24.27% |
* Healthcare Sector Average
SE:BIOSGN
Biosergen AB
0.53
-5.23
-90.80%
SE:BINV
BioInvent International AB
22.25
-6.45
-22.47%
SE:XBRANE
Xbrane Biopharma AB
10.60
-21.08
-66.54%
SE:ELIC
Elicera Therapeutics AB
2.72
-2.01
-42.54%
SE:IMMU
Immunicum AB
6.51
-0.19
-2.84%
SE:CANTA
Cantargia AB
1.46
-1.13
-43.63%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.